Objectives: To describe the early multi-center, clinical experience with the Medtronic Micro Vascular Plug TM (MVP) in children with congenital heart disease (CHD) undergoing vascular embolization. Background: The MVP is a large diameter vascular occlusion device that can be delivered through a microcatheter for embolization of abnormal blood vessels. Methods: A retrospective review of embolization procedures using the MVP in children with CHD was performed in 3-centers. Occlusion of patent ductus arteriosus using the MVP was not included. Results: Ten children underwent attempted occlusion using the MVP. The most common indication to use the MVP was failed attempted occlusion using other embolic devices. Five, single ventricle patients (median age 3-years, median weight 14.9 kg) underwent occlusion of veno-venous collaterals following bidirectional Glenn operation. Three patients (Median age 8 years) underwent occlusion of coronary artery fistulae (CAF). Two patients (age 7 months and 1 year) underwent occlusion of large aorto-pulmonary collaterals. A 7-day-old child with a large CAF required 2 MVPs and an Amplatzer Vascular Plug (AVP-II) for complete occlusion. Occlusion of all other blood vessels was achieved using a single MVP. One MVP embolized distally in an 8-years-old child with a large CAF. There were no other procedural complications or during follow-up (median 9 months). Conclusions: The MVP is a new, large-diameter vascular embolization device that can be delivered through a microcatheter. It may play an important role in providing highly effective occlusion of abnormal vessels in children.
Introduction
Children with congenital heart diseases (CHD) often develop abnormal blood vessels that may require transcatheter embolization, prime examples of which are aorto-pulmonary collaterals (APCs) and venovenous collaterals (VVCs) found in children following single ventricle palliative surgeries. [1] [2] [3] [4] [5] APCs and VVCs occur commonly after the superior cavo-pulmonary connection (Glenn operation). 5 APCs have been associated with persistent pleural effusions and other perioperative morbidities after Fontan completion. [6] [7] VVCs on the other hand decompress systemic venous blood to the pulmonary veins or inferior vena cava, leading to cyanosis. 5 Transcatheter occlusion of significant APCs and VVCs are a mainstay in the management of children with single ventricle physiology. [8] [9] Abnormal blood vessels in children are not only sequelae of surgery for congenital heart disease, but may also be congenital, an example is congenital coronary artery fistulae (CAFs) which are often highly convoluted. [10] [11] Occlusion of such abnormal blood vessels in small children with highly tortuous anatomies has always been a challenge for pediatric interventional cardiologists. [12] [13] A number of embolization coils and occlusion devices are available for occlusion of abnormal blood vessels in children. Many occlusion devices like the Amplatzer Vascular Plugs (St. Jude Medical, St. Paul, MN) require a relatively large delivery system, or a stiff delivery cable that often precludes their use in small children. [12] [13] Despite numerous modifications to address delivery catheter/sheath size, there is no single device that has proven versatile enough to address this problem. This is partly due to the varying anatomy of these collaterals and fistulae. When these lesions are highly tortuous, it may be impossible to cannulate such vessels using a large lumen catheter. In other instances, catheters may kink while negotiating a tight curve, while stiffer catheters and delivery sheaths risk injuring these abnormal vessels and could lead to potentially serious complications. Accordingly, many a time, the only catheter that can safely negotiate the tortuous and abnormal anatomies of APCs, VVCs, and CAFs are microcatheters. However, large diameter embolization devices cannot be delivered through a microcatheter.
The Medtronic Micro Vascular Plug TM (MVP) is an FDA approved and CE marked product. It has been used for vascular embolization in neuro-interventional and other interventional radiology procedures, mostly in adults. [14] [15] [16] [17] [18] Since the MVP is a large diameter vascular occlusion device that can be delivered through a microcatheter, it may be ideally suited for use in children with CHD. The objective of this study was to describe the early, multi-center clinical experience with the MVP in children with underlying CHD undergoing vascular embolizations.
Materials and Methods
Device. The Medtronic Micro Vascular Plug TM is the first ever plug that can be delivered through a microcatheter. It is a large diameter, controlled, detachable, and resheathable embolic device. The MVP's cage design is composed of a nitinol framework covered partially by a polytetrafluoroethylene (PTFE) membrane at the proximal portion (Fig. 1) . Unlike the Amplatzer TM Vascular Plugs II and 4 (AVP II and AVP 4, St. Jude Medical, St. Paul, MN), the MVP has no discs. It is held in place by oversizing of the device to the target vessel diameter and the partial PTFE covering enables rapid occlusion. The delivery cable is a 180 cm long, 0.018-inch nitinol wire. Tracking through the tortuous course of the microcatheter is facilitated by the highly flexible delivery wire and device. There are proximal and distal radio-opaque markers. The 5.3 mm (MVP-3Q) and 6.5 mm (MVP-5Q) devices that can be introduced through microcatheters of inner diameters of 0.021" and 0.027" respectively. The maximal constrained length is 15 and 16 mm for the MVP-3Q and MVP-5Q, respectively, while the unconstrained length is 12 mm for both device sizes. It is recommended that the MVP-3Q is used for target vessel diameters between 1.5 and 3 mm, and the MVP-5Q for 3-5 mm vessels. The MVP-7Q with a device diameter of 9.2 mm, and MVP-9Q with a diameter of 13 mm are larger devices that require 4 and 5 French delivery catheters, respectively.
Deployment Technique. For preparation, the device is immersed in a bowl containing heparinized saline and withdrawn into the loader catheter while submerged by pulling back on the delivery wire until the distal tip of the MVP is fully sheathed. The distal end of the introducer sheath is inserted into the hub of the microcatheter which has already been positioned in the target blood vessel through a Y-connector. The system is then flushed, and the hemostasis valve is tightened. For device delivery, the pusher wire is advanced through the microcatheter until the distal platinum marker of the MVP is aligned with the distal marker of the microcatheter. The hemostasis valve is unscrewed and the device is unsheathed by slowly withdrawing the micro catheter and the delivery sheath while maintaining a constant forward pressure on the delivery cable. The position of the device is confirmed with small amounts of contrast injections through the guiding catheter through which the microcatheter is introduced. If repositioning is required, the microcatheter is advanced to recapture the device while maintaining stability of the delivery wire. The device can be redeployed using the same technique as described above. Once the device position is deemed satisfactory, it can be mechanically detached utilizing by unscrewing the delivery cable using a torque device. Study Population. This is a 3 center, retrospective, observational, IRB approved study. Between January 2015 and April 2016, all children undergoing attempted occlusion of abnormal blood vessels with the MVP were included. Occlusion of a patent ductus arteriosus (PDA) using the MVP was not included in this study, and has been reported elsewhere. 19 In some cases, the MVP was used after an initial failed attempt of closure using other available devices, while in other cases the MVP was the first device to be attempted if the anatomy was not felt to be ideal for any of the other commonly used coils or occlusion devices. Patient demographics, clinical indications, site of vascular occlusion, size of MVP, complications, use of secondary embolic devices for residual flow, clinical outcomes, and follow-up were noted.
Statistical Methods. Continuous variables are reported as median and range. Categorical data are reported as a count and percentage. No further statistical testing was performed as this is a descriptive study.
Results
During the study period, 8 children with underlying CHD underwent occlusion of abnormal blood vessels using the MVP. Table 1 summarizes the demographic and procedural details. The most common indication to use the MVP was failed attempted occlusion using other embolic devices (5/8, 62.5.5%).
Occlusion of Veno-Venous and Aorto-Pulmonary Collaterals. Five patients (median age 3 years, median weight 14.9 kg) underwent occlusion of VVCs due to cyanosis following bidirectional Glenn operation in the setting of single ventricle circulations. In patients 2-4 (Table 1) , due to the tortuous nature of the vessels and angle of approach from the access sites, deployment of AVP II devices was not possible. Deployment of MVP devices was then attempted (different access site in 2 patients, same access site in 1 patient) and was successful in all 3 patients. The deployment was straightforward and due to its low profile, the MVP device easily traversed the areas of acute turn ( Fig. 2A and B) that were not possible to negotiate with AVP II devices. Two patients (patients 7 and 8, Table 1 ) had a tortuous decompressing VVC from the innominate vein to the coronary sinus. The approach was from the right internal jugular vein in both. A 4-French Glide catheter (Terumo, Tokyo, Japan) could not be advanced further than the ostium of the VVC without kinking the catheter. A HI-FLO TM Renegade TM microcatheter (Boston Scientific, Marlborough, MA) was therefore introduced further. The MVP-5Q advanced easily through the microcatheter in both these cases. Immediate complete occlusion was demonstrated in these 2 cases by an angiogram performed through the Y-adaptor attached to the end of the glide catheter.
One patient (patient 1, Table 1 ) with tricuspid atresia after bidirectional Glenn operation was found to have a tortuous APC from the right internal mammary artery (RIMA) to the right pulmonary artery (RPA). She underwent proximal occlusion of the RIMA using the MVP-5Q after the distal vessel was occluded using a coil. Patient 9 in Table 1 was a 7-months-old girl with a large APC to the right lower lobe from the descending thoracic aorta. The child had no associated intra-cardiac anomaly. The APC was providing dual blood supply to these segments of the right lung along with the right lower pulmonary artery. Therefore, decision was made to occlude the APC. The APC measured 5-6 mm proximally, 11 mm in the mid dilated segment, and 9 mm distally. A 5-French delivery sheath was used to implant a 12 mm AVP-II and a 10 mm AVP-II distally. However, there still was residual shunting through the devices. Therefore, an MVP-7Q device was used to occlude the APC proximally through a 5-French glide catheter with complete occlusion demonstrated by angiography.
Complete vessel closure was achieved in these patients undergoing collateral vessel occlusion with no procedural or long follow up complications (median follow up 7 months, range 4-12 months).
Occlusion of Coronary Artery Fistulae. Two patients underwent successful occlusion of CAFs. The first was a small-to-moderate sized fistula from the left circumflex coronary artery to the left atrium (Fig. 3A) in an 11-year-old (patient 6, Table 1 ). The diameter at the site of entry into the left atrium was 1.2 mm, while the coronary artery just proximal to the fistula measured
Journal of Interventional Cardiology 179 3.8 mm. The circumflex coronary artery measured 4.2 mm. A HI-FLO TM Renegade TM microcatheter was introduced through a guide catheter and manipulated through the fistula (Fig. 3B ) over a 0.014 guidewire. An MVP-5Q was delivered into the coronary fistula. Angiograms were performed through the guide catheter to ascertain proper positioning of the MVP (Fig. 3C) . A left coronary angiogram was repeated 15 minutes after MVP deployment that demonstrated complete occlusion of the fistula (Fig. 3D) . On 6 months' follow-up, the patient has been symptom free with no shunting observable on echocardiogram.
The second patient (patient 5, Table 1 ) was a 1 week old 3.9 kg neonate with a large left coronary artery to left ventricle fistula and heart failure (Fig. 4) . The minimal diameter of the fistula was 3 mm with an aneursymal portion measuring 6.4 mm. The patient underwent deployment of an 8 mm AVP II device at the site on drainage into the left ventricle. However, a proximal dilated area of the fistula remained patent. Therefore, 2 MVP-5Q Figure 2 . Occlusion of veno-venous collaterals using the MVP. In this 4-year-old child after bidirectional Glenn operation, a systemic venous to pulmonary venous collateral was found originating from the superior vena cava and draining to the right upper pulmonary vein. The vessel was not easily accessed from the right internal jugular vein. (A) An AVP device was not able to traverse the angulated segment from a femoral venous approach, due to the acute and posterior angulation, arrow. (B) An MVP easily traversed this area, arrow and was deployed successfully with no residual flow. devices were implanted more proximally in order to minimize the formation of thrombus in the aneurysmal portion of the left coronary artery. This resulted in complete occlusion of the fistula. MVP devices were chosen in order to conform better to the aneurysmal portion of the proximal fistula and not protrude into the aorta. The patient has done well on follow up at 6 months with resolution of heart failure symptoms. The third patient was an 8 year old (patient 10, Table 1 ) with a large left main coronary artery to right atrial fistula (Fig. 5) . The minimal diameter of the fistula in the midportion was 5 mm. The tortuous course was felt to be favorable for an MVP device. An MVP-7Q device was advanced through a 4 Fr glide catheter through a 6 Fr JL guide catheter to the midportion of the fistula. After it was released, it embolized distally to the connection to the right atrium in a stable position. No further devices were implanted in the fistula and the device was stable due to a small fistulous connection to the right atrium. The patient may need to undergo implantation of further devices or coils if there is not complete occlusion of the fistula on follow up.
Discussion
The Medtronic Micro Vascular Plug TM is a selfexpanding vascular occlusion device. The MVP device is ovoid in shape and comprised of a nitinol frame which is secured at both ends with platinum marker bands. The device is partially covered with PTFE. A number of products are available for endovascular occlusion of vessels including coils, and plug devices such as the Amplatzer TM Vascular Plugs. 20 There are unique advantages and limitations with each of these products. No single method of vessel occlusion is universally applicable, especially when dealing with small children with complex and varying anatomy. In this series, all patients underwent successful implantation of an MVP. None of the patients had residual shunts requiring a secondary occlusion device. There were no immediate or long-term device-related complications. There was 1 device embolization in our current report. On further review of the angiograms, it appeared as if the device was slightly "tangential" to the target vessel wall due to the tortuous course. As the MVP device is soft and has a low profile this is an important point to consider, particularly in high flow states. A larger cohort of pateints will be needed to identify risk factors for embolization. Based on our experience however, it seems as if the device sizing recommended by the manuafacturer for other lesions, is generally applicable to the congenital heart disease lesions we describe.
Although both MVP and AVP are delivered using a delivery wire, and both can be resheathed and repositioned as necessary, the MVP has the advantage of being deliverable through a microcatheter. In this series, it was feasible to navigate the MVP into small vessels like collaterals, and through tortuous vessels like coronary artery fistulae. Due to its low profile, the MVP can be delivered through a microcatheter which minimizes vessel trauma and hemodynamic instability encountered with large delivery systems when traversing cardiac structures in tiny neonates. As seen in our experience, due to its low profile, the MVP is able to navigate very tortuous turns that are at times not possible with slightly bulkier devices. It is possible that in the cases in which we changed access sites, the same results could have been achieved with other devices. After exhaustive attempts using the AVP-II, we decided to try the MVP. Earlier in our experience, we changed the access site hoping that it might help us. In retrospect, now that we understand the ease with which the MVP traverses tortuous collaterals, we likely could have achieved the MVP implantation through the same access site as we did in our other patients. Although some coils are also deliverable through microcatheters, the MVP has advantages over coils in that it is a much larger diameter device that offers more control due to the delivery mechanism with a delivery cable. Moreover, the MVP can achieve immediate vessel occlusion because of the PTFE covering. The MVP is a fairly long device in comparison to other types of vascular plugs. Therefore, the occlusion site should be long enough to accommodate the implanted MVP to prevent unintended obstruction of adjacent normal vessels.
Animal testing has shown that the MVP endothelializes and promotes thrombus formation before the endothelialization process (personal communication, Medtronic), similar to other devices. The device has to be oversized to prevent device migration, as it is selfexpanding. A target vessel diameter of 1.5-3 mm for the MVP-3Q device and 3-5 mm for the MVP-5Q device is recommended by the manufacturer. While we have seen small tears in the PTFE covering with repeated use during bench top testing, we have not encountered tears of the PTFE membrane when loading/resheathing any of the MVP devices in a clinical setting. Care should be taken when manipulating the MVP device, particularly when multiple attempts at deployment are necessary. Small tears of the PTFE membrane might go undetected in clinical use, but large tears should be suspected if there is failure to achieve complete closure of the vessel. A disadvantage of the MVP is that apart from the proximal and distal markers, it is not radio-opaque, making it more difficult to visualize under fluoroscopy when compared to other devices. However, we have not found that to be a significant challenge in children.
Another use for the MVP would be for occlusion of PDA in extremely low birth weight (ELBW) babies. 19 Unlike in older children, the morphology of the PDA seen in these patients is less variable. 21 These PDAs are long, tubular, tortuous and with only minimal taper from the aortic to the pulmonary end. Therefore, the MVP may be ideally suited for transcatheter occlusion of the PDA in ELBW babies. Careful patient selection and precise device positioning may be prudent while choosing this device for PDA occlusion. Changes in length of the device may be required if this device were to be ideal for the routine use for closure of PDAs in ELBW babies.
The MVP has found several applications in neurointerventional procedures maneuvering microcatheters through small and tortuous lesions, it was even well suited for high-flow carotid cavernous fistulae. 17 It has found application in a plethora of peripheral interventional procedures including for gastro-intestinal (GI) bleeds. There has been 1 pilot study assessing the feasibility of using this device for pulmonary arterio-venous malformations in adults 22 with encouraging results. The first reported use of the MVP in a child was for acute GI bleed that involved embolization of the gastroduodenal artery. 23 We suspect that there will be a growing role for this device in children with a variety of cardiovascular lesions.
Conclusions
The MVP complements the armamentarium of occlusive devices available to the pediatric interventional cardiologist. Since it can be delivered through a microcatheter, it is ideally suited to occlude tortuous CAFs, APCs, and VVCs in children. The occlusion site length should allow the implanted MVP to prevent unintended obstruction of adjacent normal vessels. The MVP may play an important role in providing highly effective occlusion of abnormal vessels in children with a variety of cardiovascular conditions.
